Global Parkinson’s Disease Therapeutics Market - 2024-2031
The global Parkinson’s Disease Therapeutics market reached US$ 5.51 billion in 2023 and is expected to reach US$ 10.23 billion by 2031, growing at a CAGR of 8.0% during the forecast period 2024-2031.
Parkinson's disease is a progressive movement disorder of the nervous system caused by the degeneration of nerve cells in the substantia nigra, a part of the brain that controls movement. As these nerve cells die or become impaired, they lose the ability to produce dopamine, an important chemical for motor control. According to the American Association of Neurological Surgeons (2024), Parkinson’s symptoms typically develop when there is an 80% or greater loss of dopamine-producing cells in the substantia nigra.
Epidemiologically, the Parkinson's Foundation reports that nearly 90,000 people are diagnosed with Parkinson's disease in the U.S. each year, marking a 50% increase from the previous estimate of 60,000 diagnoses annually. Most Parkinson's patients are treated with medications that either stimulate the remaining cells in the substantia nigra to produce more dopamine (levodopa medications) or inhibit some of the acetylcholine produced (anticholinergic medications), thus restoring the chemical balance in the brain to alleviate symptoms.
Market Dynamics: Drivers & Restraints
Introduction of Innovative Therapeutics
The introduction of innovative therapeutics is expected to significantly boost the Parkinson's disease therapeutics market by expanding treatment options and enhancing patient outcomes. Recent advancements in medical research have led to the development of new therapies that specifically target various pathways involved in the disease.
New advanced therapies, including dopamine agonists, MAO-B inhibitors, and innovative drug delivery systems, are being developed to address different stages and severities of Parkinson's disease. For instance, in October 2024, AbbVie received the U.S. Food and Drug Administration (FDA) approval for VYALEV (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD).
In addition to these advancements, increased investment in research and development from both pharmaceutical companies and government entities is fostering innovation for Parkinson’s disease therapeutics which is expected to contribute to the market growth. For instance, In fiscal year 2022, the NINDS funded approximately $125 million out of a total of $259 million in NIH-supported PD research.
Collaborative efforts between biotech firms and research institutions are accelerating the discovery of new drugs and therapies, resulting in a surge of clinical trials focused on evaluating novel treatment candidates. This collaborative environment is crucial for bringing effective therapies to market more rapidly.
Presence of alternative treatments
The presence of alternative treatments is likely to impede the growth of the Parkinson's disease therapeutics market by offering patients a range of non-pharmacological options that they may find more attractive or effective. Individuals are practicing complementary and alternative therapies, including herbal supplements, acupuncture, and lifestyle changes, in their quest for symptom relief.
As these options become more popular, patients might choose them over traditional pharmacological treatments, which could reduce the demand for established medications and pose challenges for pharmaceutical companies in maintaining their market presence. For instance, according to a study published by the National Institute of Health (NIH) in 2024, of 367 people with PD, 36% reported having used natural health products to alleviate PD-related symptoms, with coffee, cannabis, and turmeric being the most popular. Furthermore, 71% of people with PD were interested in learning more about natural health products. Thus, the presence of alternative options for Parkinson’s disease could hinder the Parkinson’s disease therapeutics market.
Segment Analysis
The global Parkinson’s disease therapeutics market is segmented based on disease type, drug class, route of administration, distribution channel, end-user, and region.
Drug Class:
Drug class segment is expected to dominate the global Parkinson’s disease therapeutics market share
Drug class segment is expected to dominate the global Parkinson’s disease therapeutics market. This is due to the rising number of approvals of the drugs, the increasing number of drug launches and the increasing demand for this treatment option is expected to hold the segment in the dominant position. Moreover, ongoing clinical trials and research initiatives are expected to yield promising new therapies, thereby expanding the drug class offerings within the market. The focus on combination therapies that leverage the strengths of multiple drug classes is also likely to drive growth, as these approaches can provide more comprehensive symptom management. For instance, in September 2024, Amneal Pharmaceuticals, Inc. launched CREXONT (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets. CREXONT is now broadly available at U.S. pharmacies.
Collectively, these factors position the drug class segment as a leader in the Parkinson's disease therapeutics market, ensuring sustained growth and innovation in treatment options for patients.
Geographical Analysis
North America is expected to hold a significant position in the global Parkinson’s disease therapeutics market share
The North American region, particularly the United States, is projected to maintain the largest market share in the Parkinson's disease therapeutics market throughout the forecast period. This dominance is primarily due to the strong presence of major pharmaceutical companies that are actively developing advanced therapeutics for Parkinson's disease. A large number of market players in the pharmaceutical industry are present in North America particularly the United States, which enhances the availability and innovation of treatment options.
The increasing demand for Parkinson's disease therapeutics is driven by a growing incidence of the disease. For instance, according to the report published by the National Institute of Neurological Disorders and Stroke in 2024, Parkinson’s disease (PD) is a chronic, progressive movement disorder that affects the lives of between 500,000 and 1 million Americans.
Market players in the region are increasingly innovating new therapeutics and solutions to meet the growing requirement for solutions for Parkinson’s disease. Several companies are conducting vigorous research and clinical trials to innovate advanced solutions in the region. For instance, Neuron23 Inc. unveiled details around its global Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant, potent and selective inhibitor of LRRK2, in people with early Parkinson’s disease (PD). The NEULARK trial represents a significant advancement in precision medicine, utilizing a state-of-the-art digital biomarker and patient stratification approach to identify individuals with LRRK2-driven PD who may be most likely to respond to treatment with NEU-411.
Asia Pacific is growing at the fastest pace in the global Parkinson’s Disease Therapeutics market
The Asia-Pacific is growing at the fastest pace in the global Parkinson’s disease therapeutics market. Countries like India, China, and Japan significantly contribute to this trend, resulting in a larger patient base and heightened healthcare demand. This growth is further supported by substantial investments in research and development from both public and private sectors, which are fostering innovation in treatment options. This is due to the increasing number of cases linked to a rapidly aging population.
Additionally, the expiration of patents for several well-established drugs opens doors for new market entrants and generic manufacturers, allowing them to gain a foothold in this expanding market.
Competitive Landscape
The major global players in the Parkinson’s Disease Therapeutics market include AbbVie Inc., Acadia Pharmaceuticals Inc., ZAMBON COMPANY S.P.A., Eisai Co., Ltd., Acorda Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd., Novartis AG, Boehringer Ingelheim International GmbH and Bausch Health Companies Inc. among others.
Key Developments
• In September 2024, AbbVie announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. Tavapadon is an investigational D1/D5 dopamine receptor partial agonist being studied as a once-daily treatment for Parkinson's disease.
Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.
The Global Parkinson’s Disease Therapeutics market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2023
• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Disease Type
- 3.2. Snippet by Drug Class
- 3.3. Snippet by Route of Administration
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by End-User
- 3.6. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Introduction of innovative therapeutics
- 4.1.2. Restraints
- 4.1.2.1. Presence of alternative treatments
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter’s Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Patent Analysis
- 5.5. Regulatory Analysis
- 5.6. SWOT Analysis
- 5.7. Unmet Needs
- 6. By Disease Type
- 6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 6.1.2. Market Attractiveness Index, By Disease Type
- 6.2. Familial Parkinson’s Disease*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Idiopathic Parkinson’s Disease
- 6.4. Induced Parkinsonism
- 6.5. Others
- 7. By Drug Class
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 7.1.2. Market Attractiveness Index, By Drug Class
- 7.2. Dopamine Agonists*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Peripheral Decarboxylase Inhibitors
- 7.4. Adenosine Blockers
- 7.5. Catechol-O-methyltransferase (COMT) Inhibitors
- 7.6. Others
- 8. By Route of Administration
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 8.1.2. Market Attractiveness Index, By Route of Administration
- 8.2. Oral*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Transdermal
- 8.4. Intravenous
- 9. By Distribution Channel
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.1.2. Market Attractiveness Index, By Distribution Channel
- 9.2. Hospital Pharmacies*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Retail Pharmacies
- 9.4. Online Pharmacies
- 10. By End-User
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.1.2. Market Attractiveness Index, By End-User
- 10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Specialty Clinics
- 10.4. Others
- 11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.8.1. U.S.
- 11.2.8.2. Canada
- 11.2.8.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.8.1. Germany
- 11.3.8.2. U.K.
- 11.3.8.3. France
- 11.3.8.4. Spain
- 11.3.8.5. Italy
- 11.3.8.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.8.1. Brazil
- 11.4.8.2. Argentina
- 11.4.8.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.8.1. China
- 11.5.8.2. India
- 11.5.8.3. Japan
- 11.5.8.4. South Korea
- 11.5.8.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
- 13. Company Profiles
- 13.1. AbbVie Inc.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Acadia Pharmaceuticals Inc.
- 13.3. ZAMBON COMPANY S.P.A.
- 13.4. Eisai Co., Ltd.
- 13.5. Acorda Therapeutics, Inc.
- 13.6. Teva Pharmaceutical Industries Ltd.
- 13.7. Kyowa Kirin Co., Ltd.
- 13.8. Novartis AG
- 13.9. Boehringer Ingelheim International GmbH
- 13.10. Bausch Health Companies Inc.
- LIST NOT EXHAUSTIVE
- 14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook